ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARVINAS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$7.26+0.29 (+4.16%)
Close on Oct 19, 2026
- Market cap
- $476.98M
- P/E (TTM)
- 45.4
- Dividend yield
- –
ARVINAS, INC. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -5.7%
- Net margin
- 2.9%
- Return on equity, FY2025
- -16.2%
Financial strength
- Current ratio
- 7.91
- Debt to equity
- 0.00
- Debt to assets
- 0.1%
- Cash to current liabilities
- 114.3%
Valuation
- P/E ratio
- 45.4
- Price to sales
- 1.51
- Price to book
- 0.85
- Dividend yield
- –